Pfizer said on Thursday it completed an acquisition worth up to $10 billion of biotech firm Metsera after winning shareholder ...

How tennis Alex Zverev, rugby's Henry Slade and cyclist Sam Brand manage their condition.

Novo Nordisk A/S growth is driven by global obesity drug demand, robust pipeline development and manufacturing scale. Read ...

Novo Nordisk has found itself in an increasingly chaotic situation as of late, with shares plunging and investor confidence ...

The drugmaker is holding a special shareholder meeting to vote on the appointment of a new board after the pharma giant lost ...

Novo Nordisk faces a shareholder backlash on Friday as the Danish drugmaker's minority investors prepare a protest vote ...

WeightWatchers' CEO said on Wednesday it planned to offer Novo Nordisk's much-anticipated Wegovy in pill form if it is ...

Signed, sealed and delivered, Metsera is finally Pfizer’s. Pfizer has completed its acquisition of the obesity biotech, ...

Novo Nordisk remains a dominant business with a strong pipeline, and current multiples are low enough to justify a buy. Read my latest analysis of NVO stock.

Novo Nordisk and Eli Lilly deny partnership with Mangoceuticals for weight-loss drugs, causing Mangoceuticals' shares to ...

Both Eli Lilly and Novo Nordisk are denying a telehealth company’s claim of having struck partnerships with the two companies ...

Pfizer enters the lucrative weight-loss drug market with a massive $10 billion Metsera acquisition, targeting a $150-200 ...